Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
Key Highlights
- ➤Caspian and Kura will host an investor webcast October 13 at 4:30 p.m. ET
- ➤KO-7246 preclinical data will be reviewed following an oral EASD presentation
- ➤KO-7246 is in IND-enabling development for potential diabetes applications
- ➤Caspian plans a Phase 1 program evaluating KO-7246 in patients with diabetes
- ➤Caspian plans to advance a second candidate for additional cardiometabolic indications
SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. (“Caspian”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced they will host an investor webcast on Tuesday, October 13 at 4:30 p.m. ET. On the call, management from the companies will provide details regarding the formation of Caspian and will also review KO-7246 data featured in an oral presentation at the 62(nd) European Association for the Study of Diabetes (EASD) Annual Meeting.
Caspian and Kura management will host a webcast and conference call on October 13, 2026 at 4:30 p.m. ET / 1:30 p.m. PT. The live webcast and replay will be available on www.kuraoncology.com under the Investors tab in the Events and Presentations section.
Get started
Create a free account to read the full story.